3rd Dry AMD Therapeutics Summit
Evvnt Promotion / evvnt
Archive
30.11.2022 - 02.12.2022 Revere Hotel Boston Common, 200 Stuart Street, 02116 Boston, Massachusetts, USA
Time: 07:50 - 12:00
Conference themes
2022 hosts the race between IVERIC Bio and Apellis for regulatory approval of the very first marketable dry AMD treatment. In addition to clinical advances, the field will see plenty of technology advances for more patient-compliant therapeutics, with the favourable one-dose gene therapy approach addition to pipelines, and optimized biomarker technology.
Join our 30+ expert speakers as we tackle the most critical roadblocks preventing your drugs getting the patients who need them.
2022 hosts the race between IVERIC Bio and Apellis for regulatory approval of the very first marketable dry AMD treatment. In addition to clinical advances, the field will see plenty of technology advances for more patient-compliant therapeutics, with the favourable one-dose gene therapy approach addition to pipelines, and optimized biomarker technology.
Join our 30+ expert speakers as we tackle the most critical roadblocks preventing your drugs getting the patients who need them.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Notes
Brochure: https://go.evvnt.com/1279770-3?pid=4832
Speakers: Abraham Scaria | Chief Scientific Officer | AGTC, Anneke Der Hollander | Senior Principal Scientist and Ophthalmology Lead | AbbVie, and more.
Brochure: https://go.evvnt.com/1279770-3?pid=4832
Speakers: Abraham Scaria | Chief Scientific Officer | AGTC, Anneke Der Hollander | Senior Principal Scientist and Ophthalmology Lead | AbbVie, and more.
Enquiries and Registration:
https://go.evvnt.com/1279770-2?pid=4832
Ms. Stephanie Nketia
General Medicine
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."
